scholarly journals Preparation of and drug release from W/O/W type double emulsions containing anticancer agents.

1983 ◽  
Vol 31 (11) ◽  
pp. 4048-4056 ◽  
Author(s):  
SHOJI FUKUSHIMA ◽  
KAZUHIKO JUNI ◽  
MASAHIRO NAKANO
Keyword(s):  
Drug Release ◽  
Anticancer Agents ◽  
Double Emulsions

Design, Synthesis and Studies on Novel Polymeric Prodrugs of Erlotinib for Colon Drug Delivery

2020 ◽  
Vol 20 ◽  
Author(s):  
Sahil Kumar ◽  
Bandna Sharma ◽  
Tilak R. Bhardwaj ◽  
Rajesh K. Singh
Keyword(s):  
Drug Delivery ◽  
Colon Cancer ◽  
Drug Release ◽  
Anticancer Agents ◽  
Release Kinetics ◽  
In Vitro Release ◽  
Specific Treatment ◽  
Drug Conjugates ◽  
Polymer Drug Conjugates

Aims: In the present study, polymer-drug conjugates were synthesized based on azo-bond cleavage drug delivery approach for targeting erlotinib as anticancer drug specifically to the colon for the proficient treatment of colon cancer. Background: Colon cancer (CC) is the third commonly detected tumor worldwide and it make up about 10 % of all cases of cancers. Most of the chemotherapeutic drugs available for treating colon cancer are not only toxic to cancerous cells but also to the normal healthy cells. Among the various approaches to get rid of the adverse effects of anticancer agents, prodrugs are one of the most imperative approaches. Objective: The objective of the study is to chemically modify the erlotinib drug through azo-bond linkage and suitable spacer which will be finally linked to polymeric backbone to give desired polymer linked prodrug. The azo reductase enzyme present in colon is supposed to cleave the azo-bond specifically and augment the drug release at the colon. Methods: The synthesized conjugates were characterized by IR and 1H-NMR spectroscopy. The cleavage of aromatic azobond resulted in a potential colon-specific liberation of drug from conjugate studied in rat fecal contents. In vitro release profiles of polyphosphazene-linked conjugates of erlotinib have been studied at pH 1.2, pH 6.8 and pH 7.4. The stability study was designed to exhibit that free drug was released proficiently and unmodified from polyphosphazene-erlotinib conjugates having aromatic azo-bond in artificial colon conditions. Results: The synthesized conjugates were demonstrated to be stable in simulated upper gastro-intestinal tract conditions. The drug release kinetics shows that all the polymer-drug conjugates of erlotinib follow zero-order release kinetics which indicates that the drug release from the polymeric backbone is independent of its concentration. Kinetic study of conjugates with slope (n) shows the anomalous type of release with an exponent (n) > 0.89 indicating a super case II type of release. Conclusion: These studies indicate that polyphosphazene linked drug conjugates of erlotinib could be the promising candidates for the site-specific treatment of colon cancer with least detrimental side-effects.

Drug Delivery Devices and Targeting Agents for Platinum(II) Anticancer Complexes

2008 ◽  
Vol 61 (9) ◽  
pp. 675 ◽  
Author(s):  
Anwen M. Krause-Heuer ◽  
Maxine P. Grant ◽  
Nikita Orkey ◽  
Janice R. Aldrich-Wright
Keyword(s):  
Drug Delivery ◽  
Drug Release ◽  
Anticancer Agents ◽  
Drug Transport ◽  
Water Solubility ◽  
Controlled Drug Release ◽  
Drug Bioavailability ◽  
Platinum Drug ◽  
Drug Delivery Devices

An ideal platinum-based delivery device would be one that selectively targets cancerous cells, can be systemically delivered, and is non-toxic to normal cells. It would be beneficial to provide drug delivery devices for platinum-based anticancer agents that exhibit high drug transport capacity, good water solubility, stability during storage, reduced toxicity, and enhanced anticancer activity in vivo. However, the challenges for developing drug delivery devices include carrier stability in vivo, the method by which extracellular or intracellular drug release is achieved, overcoming the various mechanisms of cell resistance to drugs, controlled drug release to cancer cells, and platinum drug bioavailability. There are many potential candidates under investigation including cucurbit[n]urils, cyclodextrins, calix[n]arenes, and dendrimers, with the most promising being those that are synthetically adaptable enough to attach to targeting agents.

scholarly journals Reduction-Responsive Molecularly Imprinted Poly(2-isopropenyl-2-oxazoline) for Controlled Release of Anticancer Agents

Pharmaceutics ◽  
2020 ◽  
Vol 12 (6) ◽  
pp. 506 ◽  
Author(s):  
Michał Cegłowski ◽  
Valentin Victor Jerca ◽  
Florica Adriana Jerca ◽  
Richard Hoogenboom
Keyword(s):  
Controlled Release ◽  
Drug Release ◽  
Anticancer Agents ◽  
Release Kinetics ◽  
Controlled Drug Release ◽  
Release Mechanism ◽  
Molecularly Imprinted ◽  
Responsive Materials ◽  
Future Work ◽  
Specific Trigger

Trigger-responsive materials are capable of controlled drug release in the presence of a specific trigger. Reduction induced drug release is especially interesting as the reductive stress is higher inside cells than in the bloodstream, providing a conceptual controlled release mechanism after cellular uptake. In this work, we report the synthesis of 5-fluorouracil (5-FU) molecularly imprinted polymers (MIPs) based on poly(2-isopropenyl-2-oxazoline) (PiPOx) using 3,3′-dithiodipropionic acid (DTDPA) as a reduction-responsive functional cross-linker. The disulfide bond of DTDPA can be cleaved by the addition of tris(2-carboxyethyl)phosphine (TCEP), leading to a reduction-induced 5-FU release. Adsorption isotherms and kinetics for 5-FU indicate that the adsorption kinetics process for imprinted and non-imprinted adsorbents follows two different kinetic models, thus suggesting that different mechanisms are responsible for adsorption. The release kinetics revealed that the addition of TCEP significantly influenced the release of 5-FU from PiPOx-MIP, whereas for non-imprinted PiPOx, no statistically relevant differences were observed. This work provides a conceptual basis for reduction-induced 5-FU release from molecularly imprinted PiPOx, which in future work may be further developed into MIP nanoparticles for the controlled release of therapeutic agents.

Coaxial oblique interface shearing: tunable generation and sorting of double emulsions for spatial gradient drug release

Lab on a Chip ◽  
2020 ◽  
Vol 20 (7) ◽  
pp. 1249-1258 ◽  
Author(s):  
Fangsheng Huang ◽  
Zhiqiang Zhu ◽  
Ye Niu ◽  
Yi Zhao ◽  
Ting Si ◽  
...  
Keyword(s):  
Drug Release ◽  
Spatial Gradient ◽  
Double Emulsions ◽  
One Step ◽  
Interface Shearing

We propose a coaxial oblique interface shearing (COIS) process to one-step generate and sort double emulsions for thermal- and chemical-responsive spatial gradient releases.

Enhanced intracellular delivery of Curcumin by Chitosan-Lipoic acid as reduction-responsive nanoparticles

2020 ◽  
Vol 21 ◽  
Author(s):  
Somayeh Rezaei ◽  
Soheila Kashanian ◽  
Yadollah Bahrami ◽  
Hossein Zhaleh ◽  
Luis J. Cruz
Keyword(s):  
Drug Release ◽  
Lipoic Acid ◽  
Anticancer Agents ◽  
Drug Loading ◽  
Normal Tissues ◽  
Efficient Delivery ◽  
Mean Size ◽  
Anti Tumor Activity ◽  
Assay Detection

Aim: Enhancement of anti-tumor activity of the chemotherapeutic agent CUR by redox-sensitive nanoparticle to get a deeper in-sight into cancer therapy. Background: Tumor targetability and stimulus are widely used to study the delivery of drugs for cancer diagnosis and treatment because poor cellular uptake and inadequate intracellular drug release lead to inefficient delivery of anticancer agents to tumor tissue. Objective: Studies distinguishing between tumor and normal tissues or redox-sensitive systems is using glutathione (GSH) as a significant signal. Methods: In this study, we designed Chitosan-Lipoic acid Nanoparticles (CS-LANPs) to improve drug delivery for breast cancer treatmentby efficient delivery of Curcumin (CUR). The properties of blank CS-LANPs were studied in detail. The size and the polydispersity index (PDI) of the CS-LANPs were optimized. Results: The results indicate the mean size and PDI of the blank CS-LANPs were around 249 nm and 0.125, respectively. However, the drug loading (DL) and encapsulation efficiency (EE) of the CS-LANPs were estimated to be about 18.22% and 99.80%, respectively. Com-pared to non-reductive conditions, the size of reduction-sensitive CS-LANPs increased significantly under reductive conditions. Therefore, the drug release of CS-LANPs in the presence of glutathione was much faster than that of non-GSH conditions .Moreover, the antitumor ef-fect of CS-LANPs on MCF-7 cells was determined in vitro by MTT assay, cell cytotoxicity, Caspase-3 Assay, detection of mitochondrial membrane potential and quantification of apoptosis incidence. Conclusion: CS-LANPs showed a remarkably increased accumulation in tumor cells and had a better tumor inhibitory activity in vitro. CS-LANPs could successfully deliver drugs to cancer cells and revealed better efficiency than free CUR.

Double Emulsion with Ultrathin Shell by Microfluidic Step-Emulsification

Lab on a Chip ◽  
2021 ◽  
Author(s):  
Xinjin Ge ◽  
Boris Rubinstein ◽  
Yifeng He ◽  
Frederick Bruce ◽  
Liaonan Li ◽  
...  
Keyword(s):  
Drug Release ◽  
Biomedical Applications ◽  
Double Emulsion ◽  
Controlled Drug Release ◽  
Double Emulsions ◽  
Production Techniques

Double emulsions with ultrathin shells are important in some biomedical applications, such as controlled drug release. However, the existing production techniques require two or more manipulation steps, or more complicated...

Synthesis, characterization, and drug-release behavior of novel PEGylated bovine serum albumin as a carrier for anticancer agents

2010 ◽  
Vol 119 (5) ◽  
pp. 2635-2643 ◽  
Author(s):  
Soodabeh Davaran ◽  
Davoud Asgari ◽  
Mohammad Reza Rashidi ◽  
Roya Salehi ◽  
Yadolah Omidi
Keyword(s):  
Bovine Serum Albumin ◽  
Drug Release ◽  
Serum Albumin ◽  
Anticancer Agents ◽  
Bovine Serum ◽  
Release Behavior ◽  
Drug Release Behavior

scholarly journals pH-responsive polymer-based biomacromolecule nanosponges as biodegradable carriers for DOX delivery

2021 ◽  
Author(s):  
Marzieh Heidari Nia ◽  
Said Ashkar ◽  
Jose G. Munguia-Lopez ◽  
Joseph M. Kinsella ◽  
Theo G.M. van de Ven
Keyword(s):  
Drug Release ◽  
Nucleophilic Substitution ◽  
Anticancer Agents ◽  
High Capacity ◽  
Drug Carriers ◽  
Ethylene Diamine ◽  
Carboxyl Groups ◽  
Crosslinking Reaction ◽  
Beta Cyclodextrin ◽  
Release Profiles

Cellulose is the most abundant renewable biomaterial on earth and beta-cyclodextrin (BCD) is among the most commonly used biocompatible drug encapsulation agents. Combining these bio-organic materials is a very powerful approach to greatly enhance the bioavailability of many drugs. These systems also allow for optimal selective drug release profiles, high biocompatibility, as well as “green nanomedicine” approaches that are eco-friendly in their synthesis and have minimal ecological toxicity. herein, we designed a new type of green and biopolymer-based nanosponge drug carriers which is polymerized by crosslinking beta-cyclodextrin ethylene diamine (βCD-EDA) with bifunctional hairy nanocellulose (BHNC). BHNC contains, besides aldehyde groups, carboxyl groups which can react with amino groups in βCD-EDA. Firstly, the crosslinker βCD-EDA was obtained through a simple nucleophilic substitution reaction between beta-cyclodextrin carbonyl imidazole (βCD-CI) and ethylene diamine (EDA). Secondly, BHNC was functionalized with the crosslinker βCD-EDA through a facile nucleophilic substitution crosslinking reaction of the BHNC activated carboxyl groups by the amines of βCD-EDA. We refer to the polymerized highly crosslinked BHNC-βCD-EDA network as BBE. Various ratios of βCD-EDA and BHNC were polymerized with the help of DMTMM as an activator, which resulted in different morphological shapes of BBE, and thus in different release profiles and pH-responsiveness. Unlike other polymer-based βCDs and nanosponges, these new types of crosslinked polymer were prepared in a green and safe solvent (water) and with very short reaction times and at low temperatures. Finally, the BBE polymers were tested as biocompatible nanocarriers for controllable doxorubicin (DOX) delivery. These hyper crosslinked polymers show a high capacity for loading DOX with extended drug release. Furthermore, breast cancer cell cultures show lower cell viability when DOX was loaded in various BBEs than control samples or DOX alone, indicating that our DOX-BBE drug delivery systems are better anticancer agents than DOX alone.

Sign in / Sign up

Export Citation Format

Share Document